Zenas BioPharma Funding Shifts Focus From Survival Risk To Execution Risk [Yahoo! Finance]
Zenas BioPharma, Inc. (ZBIO)
Company Research
Source: Yahoo! Finance
Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Zenas BioPharma (NasdaqGS:ZBIO) has completed a follow on equity offering and a convertible senior notes offering. The combined transactions provide capital for the planned U.S. commercial launch of obexelimab. Funds are also earmarked for further clinical development across the company's pipeline. Zenas BioPharma focuses on developing and commercializing therapies such as obexelimab, with an eye on U.S. market entry. For investors, the recent capital raise is tied to bringing this asset to market and continuing clinical programs, which can influence how you think about the company's execution plans and cash needs. With funding in place, the next phase centers on how Zenas BioPharma deploys this capital into launch preparation and trials. As more details emerge on timing, regulatory milestones, and commercial strategy, you will have additional data points to assess whether the current b
Show less
Read more
Impact Snapshot
Event Time:
ZBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZBIO alerts
High impacting Zenas BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
ZBIO
News
- Zenas BioPharma (ZBIO) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 MillionGlobeNewswire
- Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common StockGlobeNewswire
- ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch [Yahoo! Finance]Yahoo! Finance
- Zenas BioPharma (ZBIO) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ZBIO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" MarketBeat
ZBIO
Earnings
- 3/16/26 - Miss
ZBIO
Sec Filings
- 4/2/26 - Form SCHEDULE
- 4/2/26 - Form 4
- 4/1/26 - Form 4
- ZBIO's page on the SEC website